AspenBio Pharma, Inc. (AspenBio) has appointed Daryl J. Faulkner to the additional position of the company as interim chief executive officer (CEO), effective February 10, 2009. Faulkner assumes interim CEO’s role following the resignation of Richard Donnelly from his roles as an officer and director of AspenBio. Donnelly intends to pursue other business opportunities. The company has appointed Robert Caspari as chief operating officer and chief medical officer of the company.
Further, AspenBio Pharma said it promoted Mark Colgin to a new position of chief scientific officer.
“We are very grateful for Rich’s invaluable contribution over the last few years as the company advanced a number of important products to late stage development,” stated Faulkner. “We wish him the very best in his endeavors.”
Greg Pusey, vice chairman of AspenBio, commented: “We continue to achieve important milestones for AspenBio, including the recent addition of board members with significant industry expertise followed by the appointments of highly accomplished members to our executive management team. With today’s addition of Dr. Caspari, Daryl Faulkner has now assembled an executive team which has more than 100 years’ combined industry related experience.”